ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
ProMIS Neurosciences filed a shelf registration and prospectus supplement to offer up to $50,000,000 of common shares under an at-the-market sales agreement.
The registration statement also covers up to $200,000,000 of securities in aggregate. Sales under the Sales Agreement with H.C. Wainwright & Co. LLC may be made from time to time on Nasdaq or otherwise, and Wainwright may receive commissions up to 3.0% of gross sales. The prospectus supplement states the company may use net proceeds to advance clinical development of PMN310, for working capital and general corporate purposes. The offering is subject to market conditions and completion of sales; timing and amounts sold will be determined by market conditions and the Sales Agreement.
ProMIS Neurosciences Inc. files its annual report describing a broad pipeline of antibody and vaccine candidates for neurodegenerative and misfolded protein diseases. Its lead program, PMN310 for Alzheimer’s disease, targets toxic amyloid-beta oligomers without binding monomers or plaque.
The company has completed enrollment of 144 patients in its Phase 1b PRECISE-AD trial across 21 U.S. sites, dosing monthly at 5, 10 or 20 mg/kg or placebo over 12 months. PMN310 has shown a generally favorable safety profile to date and received FDA Fast Track designation.
Beyond Alzheimer’s, ProMIS highlights preclinical programs for TDP-43 in ALS (PMN267), alpha-synuclein in synucleinopathies (PMN442), additional ALS targets such as RACK1 and SOD1, and vaccine efforts against amyloid-beta, alpha-synuclein and TDP-43. The report also outlines a layered intellectual property strategy built on licensed University of British Columbia algorithms, disease-specific epitopes, and antibody composition-of-matter patents.
ProMIS Neurosciences Inc. reported a 2025 net loss of $39.7 million, driven mainly by higher research and development spending of $33.4 million as it advanced its PRECISE-AD Phase 1b Alzheimer’s trial, after posting net income of $2.8 million in 2024.
Cash was $6.1 million as of December 31, 2025, with total assets of $9.2 million and a shareholders’ deficit of $1.3 million, reflecting increased accrued liabilities. The company subsequently closed a financing of up to $175 million, including $75 million up front and additional proceeds tied to future warrant exercises, which it expects to fund operations through 2027.
The PRECISE-AD Phase 1b trial of lead antibody PMN310 in Alzheimer’s disease was fully enrolled with 144 patients in December 2025. Six-month assessments and a blinded interim analysis are expected in mid to early Q3 2026, with unblinded top-line data anticipated in early 2027. PMN310 has Fast Track designation from the U.S. Food and Drug Administration and has shown a favorable safety profile to date with no treatment-related serious adverse events reported.
ProMIS Neurosciences Inc. files a Form S-3 to register 13,830,592 Common Shares for resale by certain purchasers from a January 29, 2026 private placement.
The registration covers (i) 6,815,296 Common Shares sold in the private placement, (ii) 6,915,296 Common Shares issuable upon exercise of Common Share Warrants, and (iii) 100,000 Common Shares issuable upon exercise of Pre-Funded Warrants. The company will not receive proceeds from resale by the Selling Securityholders, though it will receive proceeds from any warrant exercises for cash.
ProMIS Neurosciences reports that Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. beneficially owns 895,877 shares of Common Stock, representing 9.99% of the outstanding common shares.
That 895,877 figure comprises 696,378 shares held directly and 199,499 shares issuable upon warrants; an issuance limitation on certain warrants prevents exercise that would result in ownership above 9.99%. The filing bases percentages on approximately 8,967,740 shares outstanding, reflecting a one-for-twenty-five reverse split effective November 28, 2025 and shares reported as issued as of February 3, 2026.
ProMIS Neurosciences Inc. director Williams Eugene reported an open-market purchase of company stock. He bought 2,000 Common Shares at a price of $24.40 per share, increasing his direct holdings to 12,397 Common Shares following the transaction.
ProMIS Neurosciences Inc. director Williams Eugene purchased a total of 4,000 Common Shares in open-market transactions over three days. He bought 1,000 shares at $22.53, 1,000 shares at $21.89, and 2,000 shares at $24.00. Following these purchases, he owns 10,397 Common Shares directly.
ProMIS Neurosciences Inc. received an initial ownership report from Ally Bridge–related investment entities that are ten percent owners. The filing shows indirect holdings of 943,090 Common Shares and 700,741 Warrants. The Warrants are exercisable immediately and will expire on the earlier of within 60 days of a defined Milestone Event or February 3, 2031.
The Milestone Event is the public announcement, via press release or a Form 8-K filing, of topline data from cohorts treated with single ascending doses of PMN310. The Common Shares and Warrants are held of record by Ally Bridge MedAlpha Master Fund L.P., ABG V-SIV IX Limited and ABG V-SIV X Limited, with various Ally Bridge entities and an individual able to be deemed to share beneficial ownership.
ProMIS Neurosciences Inc. Chief Development Officer Johanne Kaplan bought 1,629 common shares in an open-market purchase at $15.35 per share. After this transaction, Kaplan directly owns 3,941 common shares, modestly increasing personal equity exposure to the company.
PROMIS NEUROSCIENCES INC. has a Schedule 13G/A reporting that Armistice Capital, LLC and Steven Boyd beneficially own 504,672 common shares, representing 0.93% of the class. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., exercises voting and investment power over the shares held by the Master Fund; the Master Fund is the direct holder and disclaims beneficial ownership by virtue of the Investment Management Agreement.
The Schedule is a joint filing by Armistice Capital and Steven Boyd executed 02/17/2026 and lists shared voting and dispositive power consistent with the reported position.